RCTs examining the effect of CCB versus CCB in patients with CKD without DM [categorical outcomes]. Supplementary Table 30. RCTs examining the effect of b-blocker versus CCB in patients with CKD without DM [categorical outcomes]. Supplementary Table 31. RCTs examining the effect of b-blocker versus CCB in patients with CKD without DM [continuous outcomes]. Supplementary Table 32. RCTs examining the effect of central-acting agent versus CCB in patients with CKD without DM [continuous outcomes]. Supplementary Table 33. General population RCTs comparing ACEI diuretic versus placebo in CKD with DM subgroups [categorical outcomes]. Supplementary Table 34. General population RCTs comparing ACEI diuretic versus placebo in CKD with DM subgroups [continuous outcomes]. Supplementary Table 35. General population RCTs comparing ARB or (ACE ARB) versus ACE in CKD subgroups with and without DM. Supplementary Table 36. General population RCTs comparing CCB versus active control in CKD subgroups with and without DM. Supplementary material is linked to the online version of the paper at http://www.kdigo.org/clinical_practice_guidelines/bp.php Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus INTRODUCTION This chapter addresses the management of BP in adult CKD patients (specifically non-dialysis-dependent CKD [CKD ND]) with diabetes mellitus. Previous guidelines1,30 have used the term diabetic nephropathy or diabetic kidney disease. This Work Group decided to use the term diabetes with CKD in recognition of the fact that many patients who have co-existing diabetes and CKD do not undergo kidney biopsy and may have other forms of kidney damage with or without the changes that characterize diabetes. Examples of alternative pathologies include nephroangiosclerosis, atheromatous embolism, atherosclerotic renal artery disease, or glomerulonephritis. 